the omniab discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
Company profile
Ticker
OABI, OABIW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • SomaLogic ...
Former names
Avista Public Acquisition Corp. II
SEC CIK
OABI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
25 Mar 24
8-K
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 24
EFFECT
Notice of effectiveness
19 Dec 23
EFFECT
Notice of effectiveness
19 Dec 23
CORRESP
Correspondence with SEC
14 Dec 23
UPLOAD
Letter from SEC
13 Dec 23
POS AM
Prospectus update (post-effective amendment)
8 Dec 23
S-3
Shelf registration
8 Dec 23
424B3
Prospectus supplement
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
4
KURT A GUSTAFSON
9 Apr 24
4
MATTHEW W FOEHR
9 Apr 24
4
Charles S Berkman
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
KURT A GUSTAFSON
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
MATTHEW W FOEHR
29 Mar 24
4
MATTHEW W FOEHR
25 Mar 24
4
KURT A GUSTAFSON
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm |
Cash burn (monthly) | (no burn) | 1.00 mm | 6.77 mm | 3.21 mm | 238.67 k | (no burn) |
Cash used (since last report) | n/a | 6.71 mm | 45.30 mm | 21.51 mm | 1.60 mm | n/a |
Cash remaining | n/a | 15.10 mm | -23.50 mm | 298.09 k | 20.21 mm | n/a |
Runway (months of cash) | n/a | 15.1 | -3.5 | 0.1 | 84.7 | n/a |
Institutional ownership, Q3 2023
86.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 18 |
Closed positions | 15 |
Increased positions | 40 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 354.44 bn |
Total shares | 101.11 mm |
Total puts | 67.50 k |
Total calls | 104.00 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Acquisition LP Avista II | 27.16 mm | $96.43 mm |
JHG Janus Henderson | 7.68 mm | $39.87 bn |
BLK Blackrock | 6.77 mm | $35.12 bn |
Vanguard | 5.50 mm | $28.52 bn |
Integrated Core Strategies | 5.37 mm | $0.00 |
MCQEF Macquarie | 3.90 mm | $20.24 bn |
Millennium Management | 3.80 mm | $19.13 bn |
Chicago Capital | 3.20 mm | $16.59 bn |
William Blair Investment Management | 2.86 mm | $14.86 bn |
Rubric Capital Management | 2.85 mm | $14.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Berkman Charles S | Common Stock | Sell | Dispose S | No | No | 5.27 | 6,954 | 36.65 k | 292,617 |
8 Apr 24 | Gustafson Kurt A | Common Stock | Sell | Dispose S | No | No | 5.27 | 6,954 | 36.65 k | 176,697 |
7 Apr 24 | Foehr Matthew W | Common Stock | Payment of exercise | Dispose F | No | No | 5.31 | 18,477 | 98.11 k | 3,170,397 |
7 Apr 24 | Foehr Matthew W | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,458 | 0.00 | 3,188,874 |
7 Apr 24 | Foehr Matthew W | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 36,458 | 0.00 | 261,950 |
7 Apr 24 | Berkman Charles S | Common Stock | Option exercise | Acquire M | No | No | 0 | 13,541 | 0.00 | 299,571 |
7 Apr 24 | Berkman Charles S | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 13,541 | 0.00 | 114,566 |
7 Apr 24 | Gustafson Kurt A | Common Stock | Option exercise | Acquire M | No | No | 0 | 13,541 | 0.00 | 183,651 |
7 Apr 24 | Gustafson Kurt A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 13,541 | 0.00 | 183,954 |
1 Apr 24 | Gustafson Kurt A | Common Stock | Sell | Dispose S | No | No | 5.46 | 11,849 | 64.70 k | 170,110 |
News
Director of Lululemon Purchases Shares After Large Drop – Insider Weekends
2 Apr 24
Truist Securities Maintains Buy on OmniAb, Maintains $10 Price Target
26 Mar 24
Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying
26 Mar 24
Benchmark Reiterates Buy on OmniAb, Maintains $8 Price Target
22 Mar 24
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
21 Mar 24
Press releases
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
15 Apr 24
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
20 Mar 24